/
Countries using and  planning to introduce IPV Countries using and  planning to introduce IPV

Countries using and planning to introduce IPV - PowerPoint Presentation

tatiana-dople
tatiana-dople . @tatiana-dople
Follow
346 views
Uploaded On 2019-03-16

Countries using and planning to introduce IPV - PPT Presentation

and the global status of bOPV registration Countries using and planning to introduce IPV March 2016 status report This slide deck provides a summary per country on the status of planning for the introduction of Inactivated Poliomyelitis Vaccine IPV ID: 757025

2015 amp 2016 countries amp 2015 countries 2016 2014 march rep ipv tier january ivb world date status introduction

Share:

Link:

Embed:

Download Presentation from below link

Download Presentation The PPT/PDF document "Countries using and planning to introdu..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

Slide1

Countries using and

planning to introduce IPV

and the global status of

bOPV

registrationSlide2

Countries using and planning to introduce IPVMarch 2016 status report

This slide deck provides a summary per country on the status of planning for the introduction of Inactivated Poliomyelitis Vaccine (IPV).

It also includes a summary of the global status of national registration of bivalent Oral Polio Vaccine (

bOPV

), in preparation for the switch from trivalent OPV (

tOPV

) to

bOPV

.

Information here is updated monthly based on information shared by WHO and UNICEF Regional Offices. Please contact

polio2@who.int

with any questions or updates on this data.

Definition:

Formal decision

to introduce:

The country has documentation of its decision to introduce IPV which has been verified by the relevant WHO Regional Office, or for

Gavi

eligible countries, a complete application for IPV has been submitted to the

Gavi

Secretariat.

Tracking

these decisions and informal intents provide an indication of the global trend towards meeting the targets of the

Polio Eradication and Endgame Strategic Plan

.Slide3

Countries using IPV vaccine to date

and formal decision to introduce

Data source: WHO/IVB Database, as of 01 March 2016

Map production Immunization Vaccines and Biologicals (IVB),

World Health Organization

Date of slide: 1 March 2016

The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. ©WHO 2016. All rights reserved.

Introduced to date*

(160 countries or 82%)

(27 countries or 14%)

Formal commitment to introduce in 2016

Not Available

(7 countries or 4%)

Not applicable

Since January 2013, the following countries have introduced IPV: Kazakhstan, Peru & Singapore (July 2013); Micronesia (August 2013); Libya (April 2014); Albania & Panama (May 2014); Nepal & Tunisia (September 2014); Philippines (October 2014); China (December 2014); Comoros, Senegal & Serbia (January 2015); Colombia & Nigeria (February 2015); Bangladesh & Maldives (March 2015); DR Congo, DPR Korea & The Gambia (April 2015); Madagascar (May 2015); Cote d'Ivoire, Grenada, Kiribati, Morocco, St Vincent and the Grenadines & Sudan (June 2015); Bhutan, Cameroon, Niger, Pakistan, Philippines & Sri Lanka (July 2015); Benin, Chad, Papua New Guinea, The Former Yug. Rep. of Macedonia (August 2015); Afghanistan, CAR, Dominica, Guyana, Iran, Jamaica, Seychelles & Solomon Islands (September 2015); Bahamas, Lao People's Dem Rep, Nauru, Samoa (October 2015); Antigua and Barbuda, Botswana, Burundi, Cook Islands, Guinea, India, Mauritania, Mauritius, Mozambique, Namibia, Nicaragua, St Lucia, Suriname, Tuvalu, Vanuatu

& Yemen

(November 2015); Algeria, Belize, Cambodia, Dominical Rep, Ecuador, Ethiopia, Fiji, Gabon, Georgia, Honduras, Kenya, Myanmar, Paraguay, St Kitts & Nevis, S. Sudan, Thailand, Tonga & Trinidad & Tobago (December 2015); Cuba, El Salvador, Guatemala, Haiti, Iraq & Venezuela (Bolivian Rep of) (January 2016); Azerbaijan, Bolivia & Timor-Leste (February 2016)

Introduction delayed to 2017

* Including partial introduction in Haiti, India & Venezuela Slide4

IPV introduction status and planned introduction

in 2016-2017

Date of slide: 2 February 2016

The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. ©WHO 2016. All rights reserved.

Introduced to date*

(160 countries or 82%)

Introduction planned in March 2016

Introduction planned between May and September 2016

Not available

(14 countries or

7

%)

Not applicable

Introduction planned in April 2016

* Including partial introduction in Haiti, India & Venezuela

(9 countries or 5%)

(4 countries or

2

%)

Data source: WHO/IVB Database, as of 01 March 2016

Map production Immunization Vaccines and Biologicals (IVB),

World Health Organization

Since January 2013, the following countries have introduced IPV: Kazakhstan, Peru & Singapore (July 2013); Micronesia (August 2013); Libya (April 2014); Albania & Panama (May 2014); Nepal & Tunisia (September 2014); Philippines (October 2014); China (December 2014); Comoros, Senegal & Serbia (January 2015); Colombia & Nigeria (February 2015); Bangladesh & Maldives (March 2015); DR Congo, DPR Korea & The Gambia (April 2015); Madagascar (May 2015); Cote d'Ivoire, Grenada, Kiribati, Morocco, St Vincent and the Grenadines & Sudan (June 2015); Bhutan, Cameroon, Niger, Pakistan, Philippines & Sri Lanka (July 2015); Benin, Chad, Papua New Guinea, The Former Yug. Rep. of Macedonia (August 2015); Afghanistan, CAR, Dominica, Guyana, Iran, Jamaica, Seychelles & Solomon Islands (September 2015); Bahamas, Lao People's Dem Rep, Nauru, Samoa (October 2015); Antigua and Barbuda, Botswana, Burundi, Cook Islands, Guinea, India, Mauritania, Mauritius, Mozambique, Namibia, Nicaragua, St Lucia, Suriname, Tuvalu, Vanuatu

& Yemen

(November 2015); Algeria, Belize, Cambodia, Dominical Rep, Ecuador, Ethiopia, Fiji, Gabon, Georgia, Honduras, Kenya, Myanmar, Paraguay, St Kitts & Nevis, S. Sudan, Thailand, Tonga & Trinidad & Tobago (December 2015); Cuba, El Salvador, Guatemala, Haiti, Iraq & Venezuela (Bolivian Rep of) (January 2016); Azerbaijan, Bolivia & Timor-Leste (February 2016)

Introduction planned in 2017

(7 countries or

4

%)Slide5

Countries using IPV vaccine to date and introductions planned according to Gavi eligibility status

Data source: WHO/IVB Database, as of 01 March 2016

Map production Immunization Vaccines and Biologicals (IVB),

World Health Organization

Date of slide: 1 March 2016

The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. ©WHO 2016. All rights reserved.

Introduced to date

(160 countries or 82%)

Gavi

countries with formal commitment to introduce in 2016-17

(27 countries or 14%)

Non

Gavi

countries with formal commitment to introduce in 2016-17

(7 countries or 4%)

Not available

Not applicable

Since January 2013, the following countries have introduced IPV: Kazakhstan, Peru & Singapore (July 2013); Micronesia (August 2013); Libya (April 2014); Albania & Panama (May 2014); Nepal & Tunisia (September 2014); Philippines (October 2014); China (December 2014); Comoros, Senegal & Serbia (January 2015); Colombia & Nigeria (February 2015); Bangladesh & Maldives (March 2015); DR Congo, DPR Korea & The Gambia (April 2015); Madagascar (May 2015); Cote d'Ivoire, Grenada, Kiribati, Morocco, St Vincent and the Grenadines & Sudan (June 2015); Bhutan, Cameroon, Niger, Pakistan, Philippines & Sri Lanka (July 2015); Benin, Chad, Papua New Guinea, The Former Yug. Rep. of Macedonia (August 2015); Afghanistan, CAR, Dominica, Guyana, Iran, Jamaica, Seychelles & Solomon Islands (September 2015); Bahamas, Lao People's Dem Rep, Nauru, Samoa (October 2015); Antigua and Barbuda, Botswana, Burundi, Cook Islands, Guinea, India, Mauritania, Mauritius, Mozambique, Namibia, Nicaragua, St Lucia, Suriname, Tuvalu, Vanuatu

& Yemen

(November 2015); Algeria, Belize, Cambodia, Dominical Rep, Ecuador, Ethiopia, Fiji, Gabon, Georgia, Honduras, Kenya, Myanmar, Paraguay, St Kitts & Nevis, S. Sudan, Thailand, Tonga & Trinidad & Tobago (December 2015); Cuba, El Salvador, Guatemala, Haiti, Iraq & Venezuela (Bolivian Rep of) (January 2016); Azerbaijan, Bolivia & Timor-Leste (February 2016)

* Including partial introduction in Haiti, India & Venezuela Slide6

34 countries introducing IPV between 1 March 2016 and February 2017Tier

1 countries are countries with cVDPV2 transmission or cVDPV2

reported since 2000 & WPV endemic

countries

Tier

2 countries

are countries

with

cVDPV 1/3 since 2000 or large /medium size countries with DTP3 coverage <80% in the past

3 years as per WUENIC

Data source: WHO/IVB Database, as of 01 March 2016Map production Immunization Vaccines and Biologicals (IVB),World Health Organization

Mar-16

Apr-16

After April-16

2017

Chile

Argentina

Angola

Eritrea (Tier 3)

Congo

Cabo Verde

Armenia

Mongolia (Tier 4)

Mali

Djibouti

Burkina Faso

Tajikistan (Tier 3)

Uganda

Egypt

Ghana

Togo (Tier 4)

 

Equatorial Guinea

Indonesia

United Rep. of Tanzania (Tier 4)

 

Guinea-Bissau

Kyrgyzstan

Uzbekistan (Tier 4)

 

Lesotho

Liberia

Zimbabwe (Tier 4)

 

Sao Tome & Principe

Malawi

 

 

Swaziland

Rep. of Moldova

 

 

 

Rwanda

 

 

 

Sierra Leone

 

 

 

Turkmenistan

 

 

 

Viet Nam

 

 

 

Zambia

 

 

 

 

 

 

 

 

 

4

9

14

7

Legend

Tier 2 countriesSlide7

Tier 1 and 2 Countries using IPV vaccine to date

and formal decision to introduce

Tier 1 countries are countries with cVDPV2 transmission or cVDPV2 reported since 2000 & WPV endemic countries

Tier 2 countries are countries with

cVDPV

1/3 since 2000 or large /Medium size countries

with DTP3 coverage <80% in the past 3 years as per WUENIC

Data source: WHO/IVB Database, as of 01 March 2016,

based on 36 tier 1 & 2 countries

Map production Immunization Vaccines and Biologicals (IVB),World Health Organization

Date of slide: 1 March 2016The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. ©WHO 2016. All rights reserved.

Introduced to date*

(31 countries or 86%)

(5 countries or 14%)

Formal commitment to introduce in 2016-17

Not Applicable / not available / not Tier 1 or 2 countries

(158 countries)

Since January 2013, the following Tier 1 and 2 countries have introduced IPV:

The Philippines (October 2014), China (December 2014), Nigeria (February 2015), DR Congo (April 2015), Madagascar (May 2015), Cameroon, Niger and Pakistan (July 2015); Benin, Chad and Papua New Guinea (August 2015); Afghanistan and CAR (September 2015); Lao People's Democratic Republic (October 2015); Guinea, India, Mauritania, Mozambique, Somalia & Yemen (November 2015); Cambodia, Dominican Rep., Ethiopia, Gabon, Kenya, Myanmar & S. Sudan (December 2015); Haiti & Iraq (January 2016); Azerbaijan & Timor-Leste (February 2016)

* Including partial introduction in Haiti & India Slide8

Middle Income Countries using IPV vaccine to date

and formal decision to introduce

Data source: WHO/IVB Database, as of 01 March 2016 based on 100

middle income countries (MIC) as per last World Bank classification

Map production Immunization Vaccines and Biologicals (IVB),

World Health Organization

Date of slide: 1 March 2016

The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. ©WHO 2016. All rights reserved.

Introduced to date

(82 countries or 82%)

(94 countries)

Formal commitment to introduce in 2016-17

(18 countries or 18%)

Not applicable / not available / Non MIC

Since January 2013, the following MIC have introduced IPV:

Kazakhstan (July 2013); Peru (July 2013); Libya (March 2014); Albania (May 2014); Panama (July 2014); Tunisia (September 2014); Philippines (October 2014); China (December 2014); Senegal (January 2015); Serbia (January 2015); Colombia (February 2015);

M

aldives (March 2015) and Cote d'Ivoire, Kiribati, Morocco, St Vincent and the Grenadines & Sudan (June 2015);

Bhutan

, Cameroon,

Pakistan & Sri Lanka (July 2015

); Papua New Guinea & the former Yugoslav Rep. of Macedonia (August 2015); Dominica, Guyana, Iran, Jamaica & Solomon Islands (September 2015); Lao People's Democratic Rep & Samoa (October 2015); Botswana, India, Mauritania, Mauritius, Namibia, Nicaragua, St Lucia, Tuvalu , Vanuatu & Yemen (November 2015); Algeria, Belize, Dominican Rep, Ecuador, Fiji, Gabon, Georgia, Honduras, Kenya, Myanmar, Paraguay, Thailand & Tonga (December 2015); Cuba, El Salvador, Iraq & Guatemala (January 2016); Azerbaijan, Bolivia & Timor-Leste (February 2016)

* Including partial introduction in IndiaSlide9

Overview of Global birth cohort by

IPV status/tier(100% = 136.1million births in 2015)

Data source: WHO/IVB Database, as of

01 March

2016

and

United Nations, Department of

Economic and

Social Affairs, Population Division (2015). World Population Prospects: The 2015 Revision

IPV-using

Formal commitment to introduce in 2016 before

tOPV

/

bOPV switch

Introduction delayed after April 2016Slide10

bOPV registration status for routine immunization

Date of slide: 1 March 2016

The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. ©WHO 2016. All rights reserved.

Approval for use

(

134 countries)

Review in progress

(

2

countries)

Pending submission

(8 countries)

Not available/ non switch countries

Not applicable (switch area territories)

Data source: WHO/IVB Database, as of

01 March

2016

based on 148 OPV user countries and 7 Territories

Map production Immunization Vaccines and Biologicals (IVB),

World Health Organization

(46 countries) + 4 countries switching from tOPV to IPV